Suneva to Market and Distribute Neauvia's Plasma IQ in North America

Plasma IQ delivers focused, controlled plasma energy to create microinjuries on the skin, renewing and restoring it.

Suneva Medical, Inc., will market and distribute Neauvia Plasma IQ throughout North America as part of a new partnership.

The first Class 2 FDA-cleared plasma energy device, Plasma IQ delivers focused, controlled plasma energy to create microinjuries on the skin, renewing and restoring it. It is FDA cleared for the removal and destruction of skin lesions and the coagulation of tissue. 

"This is an exciting partnership as Suneva Medical is well positioned to offer a unique technology to a number of providers looking for new aesthetic treatments that are safe and effective," says Sean Wilson, CEO of Neauvia North America, in a news release.

"We are looking forward to welcoming Plasma IQ to our ever-expanding portfolio of facial regenerative aesthetics products," adds Pat Altavilla, CEO of Suneva Medical.  "With the introduction of Plasma IQ, we continue our commitment to providing proven and validated innovations for aesthetic providers and their patients."